Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 33.35 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 116 Open 33.35 Bid (Size) 29.44 (1) Ask (Size) 36.19 (1) Prev. Close 33.35 Today's Range 33.35 - 33.35 52wk Range 18.61 - 35.51 Shares Outstanding 67,473,870 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating September 16, 2024 A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer September 15, 2024 From Veracyte, Inc. Via Business Wire Performance YTD +21.72% +21.72% 1 Month +3.15% +3.15% 3 Month +48.22% +48.22% 6 Month +53.55% +53.55% 1 Year +47.70% +47.70% More News Read More Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors September 04, 2024 From Veracyte, Inc. Via Business Wire A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts May 08, 2024 Via Benzinga Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 26, 2024 From Veracyte, Inc. Via Business Wire Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle August 26, 2024 From Veracyte, Inc. Via Business Wire Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 August 13, 2024 Via Investor's Business Daily Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? August 11, 2024 Via Benzinga Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View August 07, 2024 Via Benzinga Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday August 07, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday August 07, 2024 Via InvestorPlace VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 Via InvestorPlace Veracyte Announces Second Quarter 2024 Financial Results August 06, 2024 From Veracyte, Inc. Via Business Wire The 3 Best Personalized Nutrition Stocks to Buy Now July 24, 2024 Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 July 17, 2024 From Veracyte, Inc. Via Business Wire Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Via Talk Markets Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness June 10, 2024 Via Benzinga Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors June 03, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer May 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in Upcoming Investor Conferences May 15, 2024 From Veracyte, Inc. Via Business Wire VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Veracyte Announces First Quarter 2024 Financial Results May 07, 2024 From Veracyte, Inc. Via Business Wire 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding May 06, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 April 22, 2024 From Veracyte, Inc. Via Business Wire New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance April 22, 2024 From Veracyte, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
